Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide
暂无分享,去创建一个
M. Elazar | J. Glenn | B. Korba | J. Rossignol | Ping Lui
[1] A. Kwong,et al. Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants , 2007, Journal of Biological Chemistry.
[2] J. Rossignol,et al. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double‐blind placebo‐controlled clinical trial , 2006, Alimentary pharmacology & therapeutics.
[3] M. Santoro,et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial , 2006, The Lancet.
[4] P. Appelbaum,et al. Activities of Tizoxanide and Nitazoxanide Compared to Those of Five Other Thiazolides and Three Other Agents against Anaerobic Species , 2006, Antimicrobial Agents and Chemotherapy.
[5] L. Saravolatz,et al. Nitazoxanide: a new thiazolide antiparasitic agent. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] R. Storer,et al. NM 283, AN EFFICIENT PRODRUG OF THE POTENT ANTI-HCV AGENT 2′-C-METHYLCYTIDINE , 2005, Nucleosides, nucleotides & nucleic acids.
[7] C. Rice,et al. Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication , 2003, Journal of Virology.
[8] C. Rice,et al. Efficient initiation of HCV RNA replication in cell culture. , 2000, Science.
[9] B. Korba,et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. , 2008, Antiviral research.
[10] E. Keeffe,et al. 68 RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 , 2008 .
[11] A. Kwong,et al. PHENOTYPIC AND STRUCTURAL ANALYSES OF HCV NS3 PROTEASE ARG 155 VARIANTS: SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON ALPHA , 2007 .
[12] J. Rinaudo,et al. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. , 2005, Antiviral research.